, Volume 78, Issue 5–6, pp 391–401 | Cite as

An Advanced LC–MS/MS Platform for the Analysis of Specialized Pro-Resolving Lipid Mediators

  • Hulda S. Jónasdóttir
  • Andreea Ioan-Facsinay
  • Joanneke Kwekkeboom
  • Hilde Brouwers
  • Anne-Marie Zuurmond
  • René Toes
  • André M. Deelder
  • Martin GieraEmail author
Part of the following topical collections:
  1. Recent Developments in Clinical Omics


Here we present an advanced platform for the analysis of specialized pro-resolving mediators (SPM), including a set of pro-inflammatory lipids and respective biochemical pathway markers. The platform is characterized by a largely simplified sample preparation protocol, employing methanol protein-precipitation instead of solid phase extraction. Sample preparation and analysis can be carried out in 96-well format, ensuring higher throughput. In addition, faster analysis times and higher sensitivities have been achieved when compared to other platforms. In total 36 lipid mediators—SPM, their pathway markers and a set of pro-inflammatory lipids including three internal standards—are analyzed within an 11 min LC–MS/MS run. The method was validated using human plasma, including repeatability, linearity, recovery, matrix effects, and accuracy. The presented platform was applied in the analysis of synovial fluid post-mortem samples and cellular extracts from polymorphonuclear cells as well as whole blood treated with ionophore in the presence of the polyunsaturated fatty acid eicosapentaenoic acid.


LC–MS Inflammation resolution Pro-resolving mediators Synovial fluid LTE4 EPA 



The presented research was partially funded by the Prof. Jan Veltkamp Fonds of the LUMC. We thank Dr. Makoto Arita from the Graduate School of Pharmaceutical Sciences at the University of Tokyo for the generous supply of synthetic standard material of RvE1, RvE2, 18R-RvE3 and 18S-RvE3.

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

10337_2014_2779_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 17 kb)
10337_2014_2779_MOESM2_ESM.docx (15 kb)
Supplementary material 2 (DOCX 15 kb)


  1. 1.
    Serhan CN, Petasis NA (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111(10):5922–5943. doi: 10.1021/cr100396c CrossRefGoogle Scholar
  2. 2.
    von Schacky C, Marcus AJ, Safier LB, Ullman HL, Islam N, Broekman MJ, Fischer S (1990) Platelet-neutrophil interactions. 12S,20- and 5S,12S-dihydroxyeicosapentaenoic acids: two novel neutrophil metabolites from platelet-derived 12S-hydroxyeicosapentaenoic acid. J Lipid Res 31(5):801–810Google Scholar
  3. 3.
    Isobe Y, Arita M, Matsueda S, Iwamoto R, Fujihara T, Nakanishi H, Taguchi R, Masuda K, Sasaki K, Urabe D, Inoue M, Arai H (2012) Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem 287(13):10525–10534. doi: 10.1074/jbc.M112.340612 CrossRefGoogle Scholar
  4. 4.
    Schif-Zuck S, Gross N, Assi S, Rostoker R, Serhan CN, Ariel A (2011) Saturated-efferocytosis generates pro-resolving CD11blow macrophages: modulation by resolvins and glucocorticoids. Eur J Immunol 41(2):366–379. doi: 10.1002/eji.201040801 CrossRefGoogle Scholar
  5. 5.
    Hsiao H-M, Sapinoro RE, Thatcher TH, Croasdell A, Levy EP, Fulton RA, Olsen KC, Pollock SJ, Serhan CN, Phipps RP, Sime PJ (2013) A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS ONE 8(3):e58258. doi: 10.1371/journal.pone.0058258 CrossRefGoogle Scholar
  6. 6.
    Serhan CN (2010) Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 177(4):1576–1591. doi: 10.2353/ajpath.2010.100322 CrossRefGoogle Scholar
  7. 7.
    Serhan CN, Recchiuti A (2012) Pro-resolving lipid mediators (SPMs) and their actions in regulating miRNA in novel resolution circuits in inflammation. Front Immunol. doi: 10.3389/fimmu.2012.00298 Google Scholar
  8. 8.
    Serhan CN, Dalli J, Karamnov S, Choi A, Park C-K, Xu Z-Z, Ji R-R, Zhu M, Petasis NA (2012) Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J 26(4):1755–1765. doi: 10.1096/fj.11-201442 CrossRefGoogle Scholar
  9. 9.
    Bannenberg G, Serhan CN (2010) Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochimica et Biophysica Acta 1801(12):1260–1273. doi: 10.1016/j.bbalip.2010.08.002 CrossRefGoogle Scholar
  10. 10.
    Kortz L, Dorow J, Becker S, Thiery J, Ceglarek U (2013) Fast liquid chromatography–quadrupole linear ion trap-mass spectrometry analysis of polyunsaturated fatty acids and eicosanoids in human plasma. J Chromatogr B 927:209–213. doi: 10.1016/j.jchromb.2013.03.012 CrossRefGoogle Scholar
  11. 11.
    Giera M, Ioan-Facsinay A, Toes R, Gao F, Dalli J, Deelder AM, Serhan CN, Mayboroda OA (2012) Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC–MS/MS. Biochim Biophys Acta 1821(11):1415–1424. doi: 10.1016/j.bbalip.2012.07.011 CrossRefGoogle Scholar
  12. 12.
    Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC–MS/MS. Anal Chem 75(13):3019–3030. doi: 10.1021/ac020361s CrossRefGoogle Scholar
  13. 13.
    Mas E, Croft KD, Zahra P, Barden A, Mori TA (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58(10):1476–1484. doi: 10.1373/clinchem.2012.190199 CrossRefGoogle Scholar
  14. 14.
    Shearer GC, Harris WS, Pedersen TL, Newman JW (2010) Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J Lipid Res 51(8):2074–2081. doi: 10.1194/jlr.M900193-JLR200 CrossRefGoogle Scholar
  15. 15.
    Strassburg K, Huijbrechts AL, Kortekaas K, Lindeman J, Pedersen T, Dane A, Berger R, Brenkman A, Hankemeier T, Duynhoven J, Kalkhoven E, Newman J, Vreeken R (2012) Quantitative profiling of oxylipins through comprehensive LC–MS/MS analysis: application in cardiac surgery. Anal Bioanal Chem 404(5):1413–1426. doi: 10.1007/s00216-012-6226-x CrossRefGoogle Scholar
  16. 16.
    Massey KA, Nicolaou A (2013) Lipidomics of oxidized polyunsaturated fatty acids. Free Radic Biol Med 59:45–55. doi: 10.1016/j.freeradbiomed.2012.08.565 CrossRefGoogle Scholar
  17. 17.
    Sala A, Kayganich K, Zirrolli JA, Murphy RC (1991) Negative ion tandem mass spectrometry of leukotriene E4 and LTE4 metabolites: identification of LTE4 in human urine. J Am Soc Mass Spectrom 2(4):314–321. doi: 10.1016/1044-0305(91)80023-Z CrossRefGoogle Scholar
  18. 18.
    Dalli J, Serhan CN (2012) Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120(15):e60–e72. doi: 10.1182/blood-2012-04-423525
  19. 19.
    Gomolka B, Siegert E, Blossey K, Schunck W-H, Rothe M, Weylandt KH (2011) Analysis of omega-3 and omega-6 fatty acid-derived lipid metabolite formation in human and mouse blood samples. Prostaglandins Other Lipid Mediat 94(3–4):81–87. doi: 10.1016/j.prostaglandins.2010.12.006 CrossRefGoogle Scholar
  20. 20.
    Oh SF, Dona M, Fredman G, Krishnamoorthy S, Irimia D, Serhan CN (2012) Resolvin E2 formation and impact in inflammation resolution. J Immunol 188(9):4527–4534. doi: 10.4049/jimmunol.1103652 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Hulda S. Jónasdóttir
    • 1
  • Andreea Ioan-Facsinay
    • 2
  • Joanneke Kwekkeboom
    • 2
  • Hilde Brouwers
    • 2
  • Anne-Marie Zuurmond
    • 3
  • René Toes
    • 2
  • André M. Deelder
    • 1
  • Martin Giera
    • 1
    Email author
  1. 1.Center for Proteomics and MetabolomicsLeiden University Medical CenterLeidenThe Netherlands
  2. 2.Department of RheumatologyLeiden University Medical CenterLeidenThe Netherlands
  3. 3.TNOLeidenThe Netherlands

Personalised recommendations